AIM Stock Overview
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
AIM ImmunoTech Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.44 |
52 Week High | US$0.75 |
52 Week Low | US$0.32 |
Beta | -0.12 |
1 Month Change | 8.05% |
3 Month Change | -8.09% |
1 Year Change | 3.99% |
3 Year Change | -80.48% |
5 Year Change | -93.05% |
Change since IPO | -99.97% |
Recent News & Updates
Shareholder Returns
AIM | US Biotechs | US Market | |
---|---|---|---|
7D | 10.7% | 0.9% | 0.4% |
1Y | 4.0% | 10.3% | 28.8% |
Return vs Industry: AIM underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: AIM underperformed the US Market which returned 29.5% over the past year.
Price Volatility
AIM volatility | |
---|---|
AIM Average Weekly Movement | 11.0% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AIM's share price has been volatile over the past 3 months.
Volatility Over Time: AIM's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1966 | 23 | Thomas Equels | https://aimimmuno.com |
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
AIM ImmunoTech Inc. Fundamentals Summary
AIM fundamental statistics | |
---|---|
Market cap | US$21.64m |
Earnings (TTM) | -US$20.77m |
Revenue (TTM) | US$193.00k |
112.1x
P/S Ratio-1.0x
P/E RatioIs AIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AIM income statement (TTM) | |
---|---|
Revenue | US$193.00k |
Cost of Revenue | US$30.00k |
Gross Profit | US$163.00k |
Other Expenses | US$20.94m |
Earnings | -US$20.77m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 02, 2024
Earnings per share (EPS) | -0.43 |
Gross Margin | 84.46% |
Net Profit Margin | -10,764.25% |
Debt/Equity Ratio | 0% |
How did AIM perform over the long term?
See historical performance and comparison